| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.69▼ | 2.69▼ | 2.69▼ | 2.69▼ | 2.64▼ |
| MA10 | 2.69▼ | 2.69▼ | 2.69▼ | 2.65▼ | 2.62▲ |
| MA20 | 2.66▲ | 2.67▲ | 2.67▲ | 2.61▲ | 2.59▲ |
| MA50 | 2.62▲ | 2.62▲ | 2.62▲ | 2.59▲ | 2.35▲ |
| MA100 | 2.61▲ | 2.60▲ | 2.59▲ | 2.58▲ | 2.74▼ |
| MA200 | 2.58▲ | 2.59▲ | 2.61▲ | 2.37▲ | 2.40▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | 0.000▲ | 0.001▲ | 0.009▲ | 0.002▲ |
| RSI | 52.181▲ | 52.911▲ | 52.897▲ | 50.325▲ | 53.550▲ |
| STOCH | 24.250 | 26.974 | 34.458 | 59.354 | 69.864 |
| WILL %R | -65.385 | -65.385 | -65.385 | -60.526 | -41.071 |
| CCI | 0.628 | 14.424 | 16.168 | 47.370 | 122.870▲ |
|
Wednesday, August 19, 2026 04:10 AM
Detailed price information for Kiora Pharmaceuticals Inc. (KPRX-Q) from The Globe and Mail including charting and trades.
|
|
Friday, August 08, 2025 04:44 AM
Revenue for the period was $0, missing the analyst estimate of $0.75 million and down from $0.02 million in Q2 2024. Clinical pipeline progress continued, with new Phase 2 trial initiations and the ...
|
|
Tuesday, July 15, 2025 05:00 PM
Kiora Pharmaceuticals, Inc. (KPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/09/26 | 2.73 | 2.75 | 2.62 | 2.62 | 10,131 |
| 22/09/26 | 2.70 | 2.80 | 2.63 | 2.71 | 7,575 |
| 21/09/26 | 2.75 | 2.75 | 2.62 | 2.68 | 6,193 |
| 18/09/26 | 2.63 | 2.85 | 2.63 | 2.76 | 49,290 |
| 17/09/26 | 2.65 | 2.70 | 2.63 | 2.67 | 20,034 |
| 16/09/26 | 2.60 | 2.6301 | 2.57 | 2.60 | 28,374 |
| 15/09/26 | 2.66 | 2.66 | 2.59 | 2.60 | 19,592 |
| 14/09/26 | 2.6998 | 2.6998 | 2.601 | 2.65 | 18,958 |
| 11/09/26 | 2.59 | 2.65 | 2.59 | 2.65 | 10,484 |
| 10/09/26 | 2.48 | 2.58 | 2.47 | 2.58 | 15,940 |
|
|
||||
|
|
||||
|
|